



(12) Translation of
European patent specification

(11) NO/EP 3329919 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/519 (2006.01)
A61K 31/38 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2020.02.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.11.06
(86)	European Application Nr.	17209455.9
(86)	European Filing Date	2012.11.09
(87)	The European Application's Publication Date	2018.06.06
(30)	Priority	2011.11.11, US, 201161559023 P 2012.03.23, US, 201261615092 P 2012.05.25, US, 201261651878 P 2012.07.25, US, 201261675513 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2776038, 2012.11.09
(73)	Proprietor	Gilead Apollo, LLC, 333 Lakeside Drive, Foster City CA 94404, USA
(72)	Inventor	HARRIMAN, Geraldine C., 50 South Arlonda Road, Charlestown, RI 02813, USA MASSE, Craig E., 122 Hamilton Street, Cambridge, MA 02139, USA HARWOOD, James, 10 Eska Drive, Ledyard, CT 06339, USA BHAT, Sathesh, 55 Riverwalk PlaceApt. 943, West New York, New York 07093, USA GREENWOOD, Jeremy Robert, 338 Prospect Place, Apt 3E, Brooklyn, New York 11238, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54)	Title	ACC INHIBITORS AND USES THEREOF
(56)	References Cited:	WO-A1-2011/080277 JEFFREY W CORBETT: "Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007 - 2008", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 19, no. 7, 1 July 2009 (2009-07- 01), pages 943-956, XP055009931, ISSN: 1354-3776, DOI: 10.1517/13543770902862180


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav


1. Forbindelse med formel:



,



, eller




5

,

eller et farmasøytisk akseptabelt salt derav.


2. Forbindelse ifølge krav 1, som har formelen:

2



eller et farmasøytisk akseptabelt salt derav.


3. Forbindelse ifølge krav 1, som har formelen:



5

eller et farmasøytisk akseptabelt salt derav.

4. Forbindelse ifølge krav 1, som har formelen:



10

eller et farmasøytisk akseptabelt salt derav.